American Medical News reported last week, “Pharmacists have called on the agency overseeing the Medicare program to allow patients to switch their prescription drug plans outside of the normal open enrollment season after beneficiaries say they were misled by insurers.” This would mean a second chance for patients who feel they were not given all the details of the plan they are now stuck with for a year.
A large proportion of ratings and reviews found on our site – MedicareDrugPlans.com – certainly demonstrate the frustration of Medicare enrollees who are not happy with their plans. We would support such a “second chance” to find a better plan. (more…)
Tagged with: American Medical News, Centers for Medicare & Medicaid Services, CMS, co-pays, enrollees, Medicare, medicaredrugplans.com, Part D, premiums, U.S. pharmacists
Today is the last day for the Medicare Part D open enrollment period. For most Medicare enrollees, those who do not have a plan by midnight tonight will face a penalty charge, which will be added to future Part D monthly premium payments.
The Medicare drug plans have certainly frustrated many seniors, who’s experiences can be found in the ratings and reviews on www.MedicareDrugPlans.com. Some of the most frequent problems with plans communicated by seniors are drugs being dropped by plan formularies mid-year; information on drug coverage was not initially made clear; co-pays were higher than expected; and customer service was often inadequate.
On the other hand, some seniors were completely satisfied with their plans. The bottom line is that you need to pick a plan now or you will pay more later.
Sharing her optimism for Medicare Part D benefits, and the discounts provided under the Affordable Healthcare Act, Secretary of Health and Human Services Kathleen Sebelius commented on Medicare.gov’s official blog: “Through the end of October, 2.65 million people with Medicare have received discounts on brand name drugs in the donut hole. These discounts have saved seniors and people with disabilities a total of $1.5 billion on prescriptions – averaging about $569 per person.”
If you’ve yet to choose your plan, you can easily compare reviews on MedicareDrugPlans.com before making the final decision. If you want to share your experiences with others then please rate your plan.
Tagged with: Affordable Healthcare Act, co-pays, customer service, discounts, donut hole, formulary, Kathleen Sebelius, Medicare, Medicare Drug Plans, Medicare.gov, medicaredrugplans.com, Open Enrollment, Part D, penalty, premiums, Secretary of Health and Human Services, seniors
Our last post highlighted the end-of-the-month release of the long-awaited generic version of Lipitor, the most popular cholesterol-lowering drug in America. Brand-name Lipitor, manufactured by drug giant Pfizer, has been one of the key contributors to American’s high drug bills for the past 15 years. A generic version will mean massive savings for some and basic affordability for many.
Last week, however, the New York Times shared that Pfizer (unsurprisingly) wants to block access to that affordable generic. Pfizer is going to offer “large discounts for benefit managers that block the use of generic versions of Lipitor” – “When patients submit a prescription for a generic version of Lipitor, they are to be given Lipitor instead.” So, those covered by the benefit managers who accept the discount will end up paying the same high co-pay, despite the availability of a lower priced drug!
These tactics by the largest drug manufacturer to keep drug prices higher are disappointing but not surprising. After all, in addition to lobbying the U.S. government to prevent safe personal drug importation, it funds programs to scare Americans away from buying its own medication at a lower price from Canada and other countries.
Pfizer’s latest move seems to only affect Americans with health insurance who, under the Pfizer/benefit manager deal, would pay $25 monthly co-pays (instead of $10 per month) – that’s $75 for a three month supply. That’s a stark contrast to Americans without health insurance who can pay $535.00 at a local CVS in New York City. By comparing prices of verified online pharmacies at PharmacyChecker.com, the uninsured may at least knock their monthly brand name Lipitor costs to $85.70.
Fortunately, due to the economics of generic drug competition, generic Lipitor prices will eventually offer great savings to the uninsured and we’ll be keeping you updated as those new products come to market.
Tagged with: brand-name, Cholesterol, co-pays, CVS, generic drugs, health insurance, insured, Lipitor, New York City, New York Times, PBM, Pfizer, pharmacy benefit managers, pharmacychecker.com, uninsured, United States